Novel therapeutic strategies for adult obese asthmatics.

Angela L Linderholm, Jennifer M Bratt, Gertrud U Schuster, Amir A Zeki, Nicholas J Kenyon

Journal: Immunology and allergy clinics of North America 2015;34(4):809-23

PMID: 25282293

Free Full Text on PubMed Central View on PubMed

Abstract

Asthma is a complex syndrome that affects an estimated 26 million people in the United States but gaps exist in the recognition and management of asthmatic subgroups. This article proposes alternative approaches for future treatments of adult obese asthmatics who do not respond to standard controller therapies, drawing parallels between seemingly disparate therapeutics through their common signaling pathways. How metformin and statins can potentially improve airway inflammation is described and supplements are suggested. A move toward more targeted therapies for asthma subgroups is needed. These therapies address asthma and the comorbidities that accompany obesity and metabolic syndrome to provide the greatest therapeutic potential.

Address: Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3100, Davis, CA, USA.; Nutrition Department, University of California, Davis, 430 West Health Sciences Drive, Davis, CA, USA; Immunity and Diseases Prevention Unit, Western Human Nutrition Research Center, United States Department of Agriculture (USDA), Agricultural Research Services (ARS), 430 West Health Sciences Drive, Davis, CA, USA.; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of California, Davis, 4150 V Street, Suite 3100, Davis, CA, USA. Electronic address: [email protected].

DOI: 10.1016/j.iac.2014.07.006

Link outs

Free resources

Full Text Sources:

Medical:

Other Literature Sources:

https://scite.ai/reports/25282293

Subscription / membership required

Full Text Sources:

MeSH Terms: Adenylate Kinase, Adult, Airway Remodeling, Arginine, Asthma, Dietary Supplements, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Inflammation Mediators, Metformin, Molecular Targeted Therapy, Obesity